Published in Healthcare Finance, Tax and Law Weekly, February 7th, 2007
In addition, based on preliminary results, the company anticipates net cash expenditures in the fourth quarter will be approximately 23% below its previous fourth quarter net cash expenditure guidance.
For the three months ended December 31, 2006, the company expects to report revenue from Zyflo sales of between $1.9 million and $2.1 million based on prescriptions filled. Sales...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.